• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by SEP Acquisition Corp

    6/4/24 7:03:19 AM ET
    $SEPA
    Blank Checks
    Finance
    Get the next $SEPA alert in real time by email
    425 1 g084269_8k.htm 8-K

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): June 4, 2024

     

    SEP ACQUISITION CORP.

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-40679   86-2365445
    (State or Other Jurisdiction   (Commission   (IRS Employer
    of Incorporation)   File Number)   Identification No.)

     

    3737 Buffalo Speedway, Suite 1750 Houston, Texas 77098

    (Address of Principal Executive Offices) (Zip Code)

     

    (713) 715-6820

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☒   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
         
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
         
    ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
         
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each Class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one share of Class A common stock and one-half of one warrant   SEPAU   The Nasdaq Stock Market LLC
    Class A common stock, par value $0.0001 per share   SEPA   The Nasdaq Stock Market LLC
    Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share   SEPAW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

      

     

     

    Item 8.01. Other Events.

     

    Based on discussions with The Nasdaq Stock Market LLC (“Nasdaq”), SEP Acquisition Corp., a Delaware corporation (the “Company”), and SANUWAVE Health, Inc., a Nevada corporation (“SANUWAVE”), determined that the combined company was unlikely to be able to meet Nasdaq listing requirements and withdrew its listing application in order to submit an application to the Cboe BZX Exchange, Inc. This application is currently under review.

     

    Important Notice Regarding Forward-Looking Statements

     

    This Current Report on Form 8-K includes forward-looking statements regarding, among other things, the plans, strategies and prospects, both business and financial, of the Company. These statements are based on the beliefs and assumptions of the management of the Company. Although the Company believes that their plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or similar expressions. The forward-looking statements are based on projections prepared by, and are the responsibility of, the Company’s management. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the Company, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. New risk factors that may affect actual results or outcomes emerge from time to time and it is not possible to predict all such risk factors, nor for the Company to assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. Neither the Company nor SANUWAVE undertakes or accepts any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

     

    Important Information for Investors and Stockholders

     

    This document relates to a proposed transaction between the Company and SANUWAVE. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor will there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Company has filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission (the “SEC”), which includes a document that serves as a prospectus and proxy statement of the Company, referred to as a proxy statement/prospectus. A proxy statement/prospectus has been sent to all of the Company’s stockholders. The Company has also filed other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of the Company are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they contain important information about the proposed transaction.

     

      

     

     

    Stockholders can obtain a copy of the Form S-4, including the proxy statement/prospectus, and other documents filed with the SEC without charge, by directing a request to: SEP Acquisition Corp., at 3737 Buffalo Speedway, Suite 1750 Houston, Texas 77098. Investors and stockholders will also be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov. INVESTORS AND SECURITY HOLDERS OF SEP ACQUISITION CORP. ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTIONS THAT SEP ACQUISITION CORP. WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SEP ACQUISITION CORP. AND THE TRANSACTIONS.

     

    No Offer or Solicitation

     

    This Current Report on Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the transactions described above and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of the Company, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

     

      

    SIGNATURE

       

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

      SEP Acquisition Corp.
         
    Date: June 4, 2024 By: /s/ R. Andrew White
      Name: R. Andrew White
      Title: President and Chief Executive Officer

     

     

      

     

    Get the next $SEPA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEPA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SEPA
    SEC Filings

    View All

    SEC Form 25-NSE filed by SEP Acquisition Corp

    25-NSE - SEP Acquisition Corp. (0001849902) (Subject)

    7/16/24 4:03:06 PM ET
    $SEPA
    Blank Checks
    Finance

    SEP Acquisition Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - SEP Acquisition Corp. (0001849902) (Filer)

    7/15/24 4:13:18 PM ET
    $SEPA
    Blank Checks
    Finance

    SEP Acquisition Corp filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - SEP Acquisition Corp. (0001849902) (Filer)

    6/26/24 7:00:40 AM ET
    $SEPA
    Blank Checks
    Finance

    $SEPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SANUWAVE Health, Inc., a Leading Provider of FDA Approved Next-Generation Wound Care Products, Enters into a Merger Agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp., a Nasdaq-Listed Company

    ·       SANUWAVE Health Inc. (OTCQB:SNWV) has entered into a definitive merger agreement with SEP Acquisition Corp. (NASDAQ:SEPA). Upon closing, the combined company is expected to trade on the Nasdaq Capital Market under the symbol "SNWV". ·       The combined company expects to receive approximately $13.0 million of gross proceeds at closing, including $12.0 million from non-redeeming holders of SEPA's Class A common stock and other PIPE investors, and $1.0 million from the SPAC sponsor converting a loan into equity on the same terms as the PIPE.  Approximately $8.5 million of capital has already been committed. ·       This funding is expected to be anchored by investors affili

    8/23/23 4:30:00 PM ET
    $SEPA
    Blank Checks
    Finance

    $SEPA
    Financials

    Live finance-specific insights

    View All

    SANUWAVE Health, Inc., a Leading Provider of FDA Approved Next-Generation Wound Care Products, Enters into a Merger Agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp., a Nasdaq-Listed Company

    ·       SANUWAVE Health Inc. (OTCQB:SNWV) has entered into a definitive merger agreement with SEP Acquisition Corp. (NASDAQ:SEPA). Upon closing, the combined company is expected to trade on the Nasdaq Capital Market under the symbol "SNWV". ·       The combined company expects to receive approximately $13.0 million of gross proceeds at closing, including $12.0 million from non-redeeming holders of SEPA's Class A common stock and other PIPE investors, and $1.0 million from the SPAC sponsor converting a loan into equity on the same terms as the PIPE.  Approximately $8.5 million of capital has already been committed. ·       This funding is expected to be anchored by investors affili

    8/23/23 4:30:00 PM ET
    $SEPA
    Blank Checks
    Finance

    $SEPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SEP Acquisition Corp

    SC 13G/A - SEP Acquisition Corp. (0001849902) (Subject)

    6/28/24 5:18:04 PM ET
    $SEPA
    Blank Checks
    Finance